The abnormal deposition of beta-amyloid proteins in the brain is one of the major histopathological hallmarks of Alzheimer's disease. Currently available intravital microscopy techniques for highresolution plaque visualization commonly involve highly invasive procedures and are limited to a small field-of-view within the rodent brain. Here, we report the transcranial detection of amyloidbeta deposits at the whole brain scale with 20 m resolution in APP/PS1 and arcA mouse models of Alzheimer's disease amyloidosis using a large-field multifocal (LMI) fluorescence microscopy technique. Highly sensitive and specific detection of amyloid-beta deposits at a single plaque level in APP/PS1 and arcA mice was facilitated using luminescent conjugated oligothiophene HS-169.
Introduction
The abnormal accumulation and spread of amyloid-beta (Aβ) deposits are implicated to play a central role in the pathogenesis of Alzheimer's disease (AD). Different conformations, aggregation states of Aβ, including Aβ monomer, oligomer, fibrillar Aβ and plaque, elicit different responses such as synaptotoxicity, neurotoxicity and inflammation (1-3). In a clinical setting, using positron emission tomography (PET) imaging with amyloid tracers such as 11 C-PIB (4), 18 F-florbetaben (5) and 18 F-florbetapir (6) , higher cortical fibrillar Aβ loads were reported in patients with AD and mild cognitive impairment compared to healthy controls (7) . As a result, amyloid PET imaging has been established as an imaging biomarker for early and differential diagnosis of AD (8) .
In vivo Aβ detection and its longitudinal monitoring in mouse models of AD amyloidosis has provided insights on the disease mechanisms and treatment effects. The detection has been possible at macroscopic level by using 3D microPET imaging with 11 C-PIB (9), 18 F-florbetapir (10), 18 F-florbetaben (11) , 18 F-flutemetamol, 11 C-AZD2184 (12) , and 125 I-labeled-antibody (13, 14) . Alternatively, optical detection of Aβ deposits can be done with ex vivo optical projection tomography (15) as well as various in vivo planar fluorescence approaches (16) and assisted with various near-infrared contrast agents, such as AOI987 (17) , CRANAD-2/-3 (18, 19) , luminescent conjugated oligothiophenes (LCOs) (20, 21) , or in 3D via fluorescence molecular tomography employing AOI987 (22) . Imaging of Aβ at a higher (mesoscopic) resolution has also been demonstrated using 19 F-and 1 H-magnetic resonance imaging (23) or using dual modalities nearinfrared magnetic resonance imaging (24) , as well as optoacoustic tomography (25) . 4 To this end, in vivo imaging of Aβ deposits at a single plaque resolution in an intact mouse brain may enable the understanding of growth dynamics of amyloid deposits at their earliest onset and evaluation of Aβ clearing therapies. As the diameter of Aβ plaques in murine models of amyloidosis range between 8-120 m, the resolution of aforementioned macroscopic and mesoscopic imaging methods is insufficient for single Aβ deposit detection (26) (27) (28) . Optoacoustic (29) and multiphoton microscopy techniques using methoxy-X04, BTA-1 and PIB (30) (31) (32) (33) have been shown capable of monitoring Aβ with m resolution. However, these techniques provide a limited field-of-view while commonly involving cranial opening, which may affect brain physiology.
We devised a large-field multi-focal illumination (LMI) fluorescence microscopy method that provides a unique combination between an extended 20 × 20 mm field-of-view as well as high spatial (~20 m) and temporal (10 Hz) resolutions (34, 35) . In the present study, we demonstrated whole brain mapping of Aβ deposits at single plaque resolution in APP/PS1 (26) and arcA (36) mouse models of AD cerebral amyloidosis mediated by HS-169 LCOs (37) . Both strains are commonly used in AD research, but differ in their Aβ pathologies. The in vivo LMI imaging results were validated by ex vivo LMI imaging and immunohistochemistry using HS-169 with anti-Aβ antibody 6E10 and anti-amyloid fibrillar conformation antibody (OC) on mouse brain sections.
Methods

In vitro binding between amyloid probes HS-169 and recombinant A42 fibrils
Recombinant A42 monomers were expressed and produced by E.coli as described previously (38, 39) . Amyloid fibrils were formed by incubating a solution of 2 μM A42 in phosphate buffer (PBS, pH 8.0). The aggregation process was monitored by a quantitative fluorescence assay based on the Thioflavin T (ThT) dye (39) . Fluorescence imaging in vitro of 2 l of 30 μM HS-169, 30 μM HS169 + 1 μM A42 fibril, and 1 μM A42 fibril mixtures were performed at 0 and 30 minutes after mixing.
Animal model
Two APP/PS1 mice (26) overexpressing the human APP695 transgene containing the Swedish (K670N/M671L) and PSEN1 containing an L166P mutations under the control of Th1 promoter and two age-matched non-transgenic littermates of both sexes (16 months-of-age) were used. In APP/PS1 mice, human Aβ42 is preferentially generated over Aβ40, but levels of both increase with age. In the brain, the Aβ42/AβFlmi decreases with the onset of amyloid deposition (26) .
Amyloid plaque deposition starts at approximately six weeks of age in the neocortex. Deposits appear in the hippocampus at about three to four months, and in the striatum, thalamus, and brainstem at four to five months. Cognitive impairment have been reported to start at seven months of age (40) . In addition, two arcAβ mice overexpressing the human APP695 transgene containing the Swedish (K670N/M671L) and Arctic (E693G) mutations under the control of prion protein promoter and two age-matched non-transgenic littermates of both sexes were used (24 months-ofage) (41) . By six months of age, arcAβ mice develop amyloid pathology affecting both the brain parenchyma and vasculature. In the parenchyma, amyloid pathology starts as intracellular punctate Aβ deposits in the cortex and hippocampus. Plaques are abundant in these areas by 9 to 15 months (42) . Severe cerebral amyloid angiopathy is also present by 9 to 15 months of age, with dense Aβ aggregates accumulating in the walls of blood vessels (42) . Cerebral amyloid angiopathy leads to hypoperfusion, impaired vascular reactivity, decreased vessel density, blood-brain barrier 6 impairment and occurrence of cerebral microbleeds (36, (43) (44) (45) (46) . Animals were housed in ventilated cages inside a temperature-controlled room, under a 12-hour dark/light cycle. Pelleted food (3437PXL15, CARGILL) and water were provided ad-libitum. All experiments were performed in accordance with the Swiss Federal Act on Animal Protection and were approved by the Cantonal Veterinary Office Zurich (permit number: ZH082/18).
In vivo and ex vivo LMI fluorescence imaging of Aβ deposits in mice
Our recently developed LMI fluorescence imaging method based on a beam-splitting grating and an acousto-optic deflector synchronized with a high speed camera was employed for this study ( Fig. 1A) (35) . Briefly, a high-repetition pulsed Q-switched, diode end-pumped Nd:YAG laser (model: IS8II-E, EdgeWave, Germany) operating at 532 nm wavelength was used for the excitation. The laser beam was first scanned by the acousto-optic deflector AOD (AA Opto-Electronic, France) at 1 kHz and then guided into a customized beam-splitting grating (Holoeye GmbH, Germany) to generate 21×21 mini-beams. The mini-beams were relayed by 4f system and then focused onto the sample (mouse brain) to generate multiple foci, as shown in Fig. 1A . After passing through the dichroic mirror, the emitted fluorescence signal was collected and focused onto the sensor plane of a high-speed camera (PCO AG, Germany).
The fluorescence LCO probe HS-169 ( Fig. 1B) was synthesized as described previously (37) . Mice Next we compared the difference between the LMI imaging and conventional wide-field imaging.
Brain sections from one APP/PS1, one arcA and one non-transgenic littermate mouse were imaged ex vivo after the in vivo imaging sessions using the aforementioned setup. The mice were sacrificed under deep anesthesia (ketamine/xylazine/acepromazine maleate (75/10/2 mg/kg body weight, i.p. bolus injection)) without prior perfusion. Horizontal brain slices of 3-mm thickness were cut in a brain matrix using a razor blade. Sections were placed on object holders wrapped with black tape. 
Image reconstruction and data analysis
Reconstruction of the LMI images was performed based on the saved raw data from the CCD camera. Firstly, local maxima in each scanning frame were identified and the excited fluorescence signals were extracted with their centroids and intensity stored for later image stitching. Since the illumination grid was well defined with equal intervals between adjacent spots, this prior information facilitated signal extraction while suppressing noise. Correction for non-uniform beam 8 intensity profile was then performed across each frame before combining the image values of local maxima to form the complete high-resolution image. Note that laser pulse energy fluctuations and other aberrations caused by optical components may necessitate additional corrections to obtain fine-tuned image quality and more uniform responsivity, however no such corrections were applied here. Fluorescence intensity (F.I.) in regions of interest (ROIs) were quantified for the dataset of in vivo (Fig. 2) and ex vivo imaging ( Fig. 3) . Full width at half maximum (FWHM) at
x-and y-axis were used for plaque size analysis. Contrast-to-noise ratio (CNR) was calculated using the in vivo LMI imaging and conventional wide-field fluorescence microscope data acquired at 100 minutes after injections into APP/PS1, arcA and non-transgenic littermate mice.
= ( 1 − 2) ÷
Where S is fluorescence intensity in the ROI; and N is the standard deviation from a region in the background.
Immunohistochemical staining and confocal microscopy
Histology and immunohistochemical investigations were performed on the mouse brain sections after PBS perfusion and ex vivo LMI imaging. Brain hemispheres were embedded in paraffin following routine procedures and were cut in 5 m horizontal sections. For immunohistochemical staining, 6E10, HS-169, and fibrillar conformation anti-amyloid antibodies OC (47) stainings were performed following protocol described earlier with nuclei counterstained by 4′,6-diamidino-2phenylindole (DAPI) (44) (Details in Supplementary Table 1 ). Histochemical staining using Hematoxylin & Eosin were performed for structural information and detecting of abnormalities in the brain. The whole brain slices of 6E10 and Alexa488, Cyanine3, OC were imaged at ×20 magnification using Pannoramic 250 (3D HISTECH, Hungary) at the ScopeM core imaging facility of the ETH for quality control of the autofluorescence and antibody specificity.
To further assess the co-localization of different channels, confocal images of arcA, APP/PS1 mice and non-transgenic littermates were further obtained at ×10, × 63 magnification in the cortex, hippocampus areas, and ×20 magnification for the whole brain slices using a Leica SP8 confocal microscope (Leica Microsystems GmbH, Germany) at the ScopeM. Sequential images were obtained by using 405 nm, 488 nm, 561 nm lines respectively. Identical resolution settings were used for the Z stacks (n = 15). Full width at half maximum (FWHM) at x-and y-axis were used for plaque size analysis using ×10 cortex confocal images for both HS-169 and 6E10 channels.
The Allen brain atlas was used for anatomical reference (48) .
Statistics
Paired two-tail student t test was used (Graphpad Prism) for comparing values between LMI imaging and wide-field imaging. All data are present as mean ± standard deviation. Significance was set at * p < 0.05.
Results
In vitro LCO binding in aggregated Afibrils
Very weak fluorescence was detected shortly after co-incubation of HS-169 with A fibrils. The signals were significantly increasing over time reaching 3756.7: 1552.2: 725.8 (a.u.) for HS169+A HS-169: Aat 30 minutes post co-incubation (Fig. 1C) .
In vivo LMI imaging using LCO exhibited stronger fluorescence signal from the brain in APP/PS1 and arcA mice compared to NTLs
After i.v. injection of HS-169 through the mouse tail vein, fluorescence intensity increase was observed in the mouse brain indicating that the probe was passing the blood-brain barrier. In general, the HS-169 fluorescence intensity increased over time in the brain from both APP/PS1 and arcA mice, although exhibiting different kinetics. In APP/PS1 mice the signal increase was slower peaking at 140 minutes ( Fig. 2A) while in arcA mice (Fig. 2C) the signal increased faster in the early phase peaking at 100 minutes. The highest signal intensity was observed at 100-140 minutes post-injection indicating specific binding rather than probe wash-in. In comparison, HS-169 fluorescence intensity remained low in the brain from non-transgenic littermates (Fig. 2B) . At 120 minutes, fluorescence signal integrated over the cortex was 663 times higher in the brain from APP/PS1 mouse and 463 times higher in arcA mouse in comparison with that in non-transgenic littermate (Fig. 2D) . Bright signal spots appeared on LMI fluorescence microscopy images, in both the brains from APP/PS1 and arcAβ mice, suggestive of single Aβ deposits. Size analysis showed that the spots detected in the brain from APP/PS1 and arcA mice are of mean 31 m, range 15-150 m, resembling typical plaque sizes ( Fig. 2E-F) . It should be noted that accuracy of the size analysis is influenced by the fluorescence blooming effect as well as the difficulty to separate two closely neighboring signal sources in the fluorescence microscope. Intriguingly, these single signal spots were observed in APP/PS1 and arcA mouse in the area overlaying the cortex after 40 minutes and remained visible until the end of data acquisition (140-160 minutes), substantiating the capacity to visualize individual plaques ( Fig. 2A-C) .
Ex vivo LMI imaging using LCO HS-169 showed stronger cortical signal in APP/PS1, arcA mice as compared to non-transgenic littermates
Ex vivo imaging was performed on mouse brain slices as well as on PBS-perfused whole brains.
Ex vivo LMI imaging revealed higher levels of cortical HS-169 accumulation in APP/PS1 and arcA mice compared to non-transgenic littermates (Fig. 3A-C) . Greater visibility and thus detection sensitivity of Aplaques were observed by LMI imaging as compared to wide-field (WF) imaging both in whole brains ( Fig. 3C-F) as well as in individual horizontal brain sections ( Fig.   3I-L) . The fluorescence signal integrated over the cortical areas was approximately 2.5 times higher in the APP/PS1 and arcA mice compared to non-transgenic mice (Fig. 3F) . The contrastto-noise ratio (CNR) was approximately 24 times higher in LMI imaging compared to wide-field images (t test, p = 0.0003) ( Fig. 3G, ROI indicated in Fig. 3C, D) . Compared to APP/PS1 mice, the HS-169 signal in the brain vasculature became more apparent in arcA mice.
Regional distribution of plaques and difference in probe binding
Immunohistochemical and histological staining were performed on horizontal brain tissue sections from APP/PS1, arcA mice and non-transgenic littermates using HS-169, 6E10, OC and DAPI ( Fig. 4) . In APP/PS1, the A plaques distributed mainly in the parenchymal regions (pronounced in the cortex and hippocampus) ( Fig. 4A, B) , and the size of plaques identified with 6E10 (mean 27 m, range 4-117 m) was larger as compared to HS-169 (mean 19 m, range 2-82 m) (Fig.   4M) . In arcA mice, both parenchymal (pronounced in the cortex, hippocampus and thalamus) and vascular deposits are detected. The plaques in arcAmice are less diffuse compared to that in APP/PS1 mice. Plaques identified by using 6E10 (mean 40 m, range 7-131 m) are also higher in diameter than HS-169 mean 27 m, range 2-117 m) in arcA mice. OC staining for fibrillar A showed good overlap with HS-169 in the cortical slices from both APP/PS1 and arcAmice ( Fig. 4N-P) . The lack of 6E10 and HS-169 signal in cortex of the non-transgenic littermate indicated highly specific binding of HS-169 to A which absent in these brains (Fig. 4R) .
Discussion
Developing tools for non-invasive detection of A deposits at high-resolution is important for understanding disease mechanism and translational development of Aβ-targeted diseasemodifying therapies. Here, we demonstrated a novel in vivo LMI imaging approach to detect brain A deposits at single plaque resolution with a large field-of-view covering the entire cortex in APP/PS1 and arcA mouse models.
In LMI imaging the out-of-focus light can be effectively rejected, due to the inherent advantage of laser beam scanning. Thus the proposed method enables minimally invasive imaging in vivo without employing craniotomy, a powerful advantage especially when it comes to longitudinal imaging of disease progression and treatment monitoring in aging mouse models of AD amyloidosis. By employing an image reconstruction algorithm that first extracts signals from small foci then superimposes them to form a high resolution image, the LMI imaging approach further enables high resolving power at a single plague level across the entire mouse cortex. Compared to laser scanning confocal microscopy, LMI imaging is a highly parallelized technique employing hundreds of illumination foci, thus enabling fast imaging speed which is crucial for mitigating motion artifacts in in vivo studies. In addition, the LMI imaging approach is optimally suited for imaging large objects up to a centimeter scale, which is not attainable with multi-photon microscopy methods that are further hindered by the lack of optimal labels with large absorption 13 cross section and longer absorption/emission wavelengths (49, 50) . Due to the small numerical aperture of the mini-beams, a large depth of focus has been further achieved, which makes the system suitable for imaging highly curved surfaces such as the mouse head. Yet, due to the lack of the optical sectioning ability, the current LMI imaging implementation can only obtain 2D information from the mouse brain.
In vivo imaging of A plaques with other imaging modalities, such as PET, confronts the challenge of an inadequate spatial resolution to distinguish individual plaques (11, 12, (51) (52) (53) . Moreover, mouse brain imaging by PET is limited by a complicated experimental setting, short half-life of positron-emitting nuclei (17) , spillover as well as severe partial volume effects (54) . MRI has been reported to detect A plaques from APP/PS1 mice (23, 55, 56) , albeit its low detection sensitivity is generally inadequate for detecting amyloid plaque due to its insufficient contrast against the surrounding tissues (56).
LMI amyloid imaging in vivo and ex vivo using HS-169 in APP/PS1 and arcA mice showed patterns generally fitting the known Adistribution in these mouse lines and was confirmed by immunohistochemistry. In APP/PS1 mice, abundant A deposits were detected in the cortex and hippocampus (26) by using immunohistochemical staining, while arcA mouse showed higher presence of cortical, hippocampal and thalamic plaques and higher load of cerebral amyloid angiopathy (36, 43) . The higher load of amyloid in the vessel wall might explain the faster kinetics of probe accumulation in arcA mice compared to APP/PS1 mice. Size analysis (28) of the A deposits detected in vivo by HS-169and ex vivo by HS-169 and 6E10 revealed comparable values to what was previously reported in both APP/PS1 (28, 57) and arcA mouse brains (36) . We observed that HS-169 stained the core of A deposits ex vivo, thus the area stained by HS-169 is smaller than that by 6E10. In addition, HS-169 stained less proportion of 6E10 plaque in APP/PS1 compared to in arcA mouse. This is probably due to the more fibrillar composition and compact plaque structure in the arcA mouse (as observed in 6E10 and OC staining, Fig. 4H, P) as compared to the larger and more diffuse plaque types in APP/PS1 (Fig. 4F, J) . In the smaller compact A deposits (Fig. 4M) , more overlapping between 6E10 and HS-169 was observed. As chemical probes such as HS-169 chiefly detect the beta-sheet structure, which is richer in the compact fibrillar A, higher similarity is expected between HS-169 and 6E10 in the arcA than in APP/PS1 mouse brain. Different amyloid composition in mouse models of amyloidosis has been reported in previous studies by using immunohistochemical staining (58) (59) (60) . In human brain, different binding property of various probes to amyloid deposits in familial AD patients with various mutation were also reported (61) . Mean diameters for HS-169 were estimated to be 19 m and 27 m for APP/PS1 and arcAβ mice respectively, which corresponds well with spot sizes of 10-30 m measured with LMI imaging in vivo. However, it indicates also that plaques sizes are underestimated (stronger in arcAβ mice) with LMI imaging using HS-169 and might limit the capability to follow individual plaque growth. Thus, in the future novel probes may be developed and tested, which show better correspondence with true Aβ plaque size (27) . APP/PS1 is a widely used animal model for AD mechanistic study (62) (63) (64) (65) (66) . The single Adeposits detection described in the current work is directly applicable to study A plaque clearance (67) (68) (69) (70) , and to monitor antibody treatment effect in the mouse models (9, 62, 71, 72) , which can currently only be achieved by craniotomy and ex vivo techniques. Serial in vivo LMI imaging of the same mice would thus significantly reduce the number of animals required for studies monitoring Aβ accumulation, compared to cross-sectional analysis with immunohistochemistry. In addition, the suggested LMI imaging method may potentially provide a new platform for detecting tau deposits (21, 73) and other protein aggregates of beta-sheet structures (74) in vivo in animal models using chemical probes. Note that we have previously shown efficacy of the single plaque detection framework in arcA mouse model (36, 45) . Yet, further studies on younger mice (to determine detection thresholds), and other mouse strains of amyloidosis such as APPswe, APPswe/PS1dE9 mice (75) are essential for corroborating the presently available results. Additional limitations include confounding factors such as the skull thickness of the mice, and vascular abnormality in the transgenic mouse lines (especially of old age), which may have influenced the detected fluorescence intensity levels.
In conclusion, we demonstrated in vivo high-resolution whole brain A imaging by LMI imaging without skull opening in APP/PS1 and arcA mouse model of AD amyloidosis. The new imaging platform offers new prospects for in vivo studies into AD-related disease mechanisms in animal models as well as longitudinal monitoring of therapeutics targeting A
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